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a  b  s  t  r  a  c  t
Conversion  of  PrPC, the  prion  protein,  to  a conformationally  altered  isoform,  PrPSc, is  the  major  pathogenic
event  in  the  transmissible  spongiform  encephalopathies,  a  family  of neurodegenerative  diseases  includ-
ing  bovine  spongiform  encephalopathy,  Creutzfeldt-Jakob  disease  and  scrapie.  Known  post-translational
modiﬁcations  to the protein  include  disulﬁde  bridge  formation,  addition  of  a  membrane  anchor  and  N-
linked  glycosylation.  We  have  previously  identiﬁed  the  pro-collagen-like  hydroxylation  of  proline  44  in
a murine,  recombinant  prion  protein  expressed  in  Chinese  hamster  ovary  cells  and  herein  report  the
identiﬁcation  of  a second  pro-collagen-like  modiﬁcation  in  this  protein.  In  a  proportion  of the  molecules,
Lys193,  within  the  C-terminal,  folded  domain  of the  protein,  is speciﬁcally  modiﬁed  to  hydroxylysineydroxylysine
-linked glycosylation
igid loop
with  subsequent  addition  of  two  hexose  units,  assumed  to  be the  collagen-like  disaccharide  modiﬁer
Gal-Glu.  Proof  of  the  existence  of  these  modiﬁcations  has  been  obtained  by  means  of  tandem  mass  spec-
trometry  and  Edman  degradation.  Molecular  dynamics  simulations  show  that  these  modiﬁcations  lead
to a  pronounced  stabilising  effect  on  the  2–2 loop,  a  region  of  PrP  crucial  for the  disease-associated
 vivo,
 or  mconversion.  If  present  in
interactions  with  ligands
. Introduction
The transmissible spongiform encephalopathies (TSEs) are a
roup of progressive, neurodegenerative disorders that may  be
cquired genetically, arise spontaneously or may  be transmitted
y ingestion or inoculation of diseased tissues. This family of fatal
iseases includes bovine spongiform encephalopathy, scrapie of
heep and Creutzfeldt-Jakob disease in humans [1]. The funda-
ental molecular event in pathogenesis of all TSE diseases is the
onversion of a normal, cell-surface glycoprotein (PrPC – cellu-
ar prion protein) to a partially protease-resistant isoform (PrPSc
 prion protein scrapie isoform) [2]. PrPSc is deposited in insolu-
le aggregates and this form of the protein is partially resistant to
Abbreviations: CAD, collisionally activated dissociation; CHO, Chinese hamster
vary; GPI, glycosylphosphatidylinositol; MS, mass spectrometry; MS/MS, tandem
ass spectrometry; PRNP, the gene encoding the prion protein; PrPC, cellular prion
rotein; PrPSc, scrapie isoform of the prion protein; PrP GPI−, prion protein lacking
he  GPI anchor; PTM, post translational modiﬁcation; recPrP, recombinant prion
rotein; TSE, transmissible spongiform encephalopathy.
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ttp://dx.doi.org/10.1016/j.ijms.2012.08.015 these  modiﬁcations  may  have  important  implications  in PrP  structure,
ay  modulate  PrP  aggregation.
© 2012 Elsevier B.V. All rights reserved.
degradation with proteases. Since there appear to be no differences
between the primary structures of PrPSc and PrPC, the conversion
is believed to be purely conformational [3].
The prion hypothesis suggests that PrPSc is the only or, at least,
major component of the infectious agent and the conformational
change of host PrPC is believed to proceed catalytically through
the use of PrPSc as a template [2]. Such a mechanism requires the
interaction of PrPSc and PrPC, either directly or through interme-
diary molecules such as polyanions or lipids, which may  also act
as cofactors aiding conversion [4–7]. The advent of several seeded
misfolding assays, in which PrPSc can convert recombinant PrP
(recPrP) to a protease-resistant isoform in vitro [8–11], suggests
that a mechanism involving templated, conformational conversion
occurs in vivo and that disease is indeed passed by ingestion or
inoculation of PrPSc-containing tissues. However, various sporadic
forms of TSE disease exist in humans [12], and possibly in cattle [13]
and sheep [14], and it is unclear what factors initiate the confor-
mational cascade in such diseases, in the absence of an exogenous
infectious agent. Whilst sporadic diseases are believed to be caused
by somatic mutations to the PRNP gene in dividing cells, which
produces PrPC protein that can spontaneously misfold, it remains
possible that a small proportion of PrPC molecules may  undergo
covalent post-translational modiﬁcations (PTMs) that cause mis-
folding and drive the disease process.
PrPC has between 208 and 220 residues, depending on species,
and the primary structure is highly homologous across mammals. A
M.A. Ritchie et al. / International Journal of Mass
Fig. 1. (a) The full sequence of murine PrPC. N- and C-terminal signal peptides
are  shown in italics and the site of attachment of the GPI membrane anchor is
underlined. A single disulﬁde bond links cystines 178 and 213. Sites of N-linked
glycosylation are in bold whilst the sites of proline hydroxylation and lysine hydrox-
ylation (this work) are highlighted with a dark background. (b) Ribbon diagram of
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lhe structured, C-terminal domain of murine PrPC (residues 124–226). The structure
as based on that of murine PrP determined by Riek et al. [24] (PDB code 1AG2) and
endered using MolMol and PovRay.
umber of physiological PTMs have been identiﬁed, which appear
ommon to all mammalian prion proteins [15,16]. The sequence of
he murine prion protein is shown in Fig. 1(a), on which sites of
TMs are highlighted. These include cleavage of N and C-terminal
ignal sequences leaving a mature protein spanning residues
3–230 (murine numbering, which is used throughout) followed
y attachment of a glycosylphosphatidylinositol (GPI) membrane
nchor at the mature C-terminus. In the ER/golgi complex, fur-
her modiﬁcations involve addition of two N-linked carbohydrate
hains to Asn180 and Asn196 [17,18] and formation of a single,
nternal disulﬁde bond. We  have also identiﬁed the pro-collagen-
ike hydroxylation of proline 44 in both recPrP expressed in Chinese
amster ovary (CHO) cells and, at least at low levels, in PrPSc puri-
ed from the brains of scrapie infected mice [19], a modiﬁcation
hat demonstrates that the N-terminal region of PrP can adopt poly-
roline II structure [20]. There have been reports of modiﬁcations to
rginine residues in the N-terminal region, although initial sugges-
ions that these are converted to citrulline remain to be conﬁrmed
21,22]. There are further reports of modiﬁcations to arginine or
ysine residues in the N-terminal region by advanced glycation end Spectrometry 345– 347 (2013) 132– 141 133
products [23]. The effects of N-terminal amino acid modiﬁcations
on the structure of PrP have largely not been studied.
The N-terminal region of PrP is rather ﬂexible but, by contrast,
the C-terminal domain of PrPC possesses typical globular struc-
ture. NMR  studies of recombinant PrP expressed in bacteria have
shown that the C-terminal region is composed of a 3-helix bundle
with two short -strands, depicted in Fig. 1(b) [24]. Conversion of
PrPC to PrPSc is associated with an increase in the -sheet con-
tent of the protein involving at least part [3], or potentially all
of the helical region of the protein [25]. Thus, post translational
modiﬁcations in this region of the protein may be more likely to
impact on PrP folding/misfolding. There have been reports of oxi-
dation of speciﬁc methionine residues [26] and a suggestion that
asparagine/aspartate residues may  be altered in PrPSc [27,28]. In
proof of principle studies, it has also been shown that conditions
that cause oxidative or nitrative modiﬁcations, or that deiminate
PrP, can lead to misfolding [29,30] and it is clear that any PTMs that
can be detected in the C-terminal domain of PrP are candidates to
impact adversely on protein folding.
Following our previous identiﬁcation of 4-hydroxyproline in the
N-terminal region of mammalian-expressed recPrP and in PrPSc
puriﬁed from mouse brains [19], herein we  report the discov-
ery of a second novel modiﬁcation to the recPrP. Lys193 was
found to be speciﬁcally converted to -hydroxylysine with sub-
sequent addition of a di-hexose unit. Both Edman degradation and
mass spectrometry have been used to characterise these modiﬁ-
cations by comparison to complement component C1q, a protein
known to contain similar modiﬁcations in its collagenous domain,
which have previously been shown to constitute the addition
of the disaccharide galactose-glucose to hydroxylysines. Molecu-
lar dynamics simulations show that disaccharide modiﬁcation of
Lys193 of PrP leads to little effect on the motion in the loop around
the modiﬁcation, but that the loop joining -sheet2 with -helix2
becomes more stable. The 2–2 loop region has been postulated
to be implicitly involved in modulating the susceptibility of PrP to
misfold, hence modiﬁcation to Lys193 may  be a candidate post-
translational modiﬁcation initiating PrP misfolding.
2. Methods
2.1. Protein production, puriﬁcation and digestion
The expression, production and puriﬁcation of aglycosyl recom-
binant PrP lacking its GPI anchor is as described previously [31].
Brieﬂy, CHO cells were grown on Cytodex 1 microcarriers (Phar-
macia) in Techne spinner ﬂasks for 3 days in serum-containing
medium, followed by a recPrP production phase in serum-free
medium. The protein accumulated in the culture medium and, after
3 days production, soluble protein was puriﬁed by means of cation
exchange chromatography eluting with a sodium chloride gradi-
ent. Fractions containing recPrP, as determined by Western blotting
techniques, were pooled and further puriﬁed by immobilised metal
afﬁnity chromatography, eluting by means of an imidazole gradi-
ent. The ﬁnal fractions contained mature length recPrP, in addition
to a 9 kDa N-terminal fragment resulting from a single proteolytic
cleavage that has previously been characterised [31].
CHO cell recPrP in 6 M urea, pH 8.5, was reduced with 5 mM
dithiothreitol and alkylated with 20 mM  iodoacetic acid then
was  dialysed against 3 M urea, 200 mM ammonium bicarbon-
ate pH 9.0. 10% (w/w)  trypsin was added and the recPrP was
digested overnight. For selected analyses, detailed in the results
section, recPrP was partially digested by the addition of 1%
(w/w)  trypsin without prior reduction or alkylation. Complement
component C1q from human serum (Sigma) was dissolved to
1 mg/ml  in 0.2 M ammonium bicarbonate pH 8.5, 2 M urea and
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as digested overnight with 5% (w/w) trypsin without prior reduc-
ion/alkylation.
.2. Mass spectrometry
Capillary HPLC columns of 180 m internal diameter were con-
tructed using a method similar to that reported by Tong et al. [32].
imply, fused silica (180 m i.d.), was slurry packed with Hichrom
18 reversed phase packing (3.5 m beads, 150 A˚ pore size) and was
erminated with a stainless steel screen (16th inch. diameter, 2 m
ore size, Valco). Samples were injected, via an external loop, low
ispersion injector (Valco) onto a home-made desalting trap and
ere washed, eluted onto the capillary column and separated by
inear gradient of increasing solvent B (where solvent A was  95:5
2O:acetonitrile with 0.05% (v/v) triﬂuoracetic acid and solvent B
as 5:95 H2O:acetonitrile with 0.05% (v/v) triﬂuoracetic acid). A
ual syringe Microgradient HPLC pump (Applied Biosystems) pro-
ided a ﬂow rate of 50 l/min, which was split to approximately
 l/min. The outlet of the column was connected, via a UV detector
214 nm)  equipped with a U-Z View ﬂow cell (LC Packings, Amster-
am, Netherlands), to the Z-spray source of a ‘Quattro II’ tandem
uadrupole mass spectrometer (Waters, Altrincham, UK) operated
n continuous ﬂow nanospray mode. The mass spectrometer was
canned from m/z 350 to 2200 (4 s per scan) and the cone voltage
as ramped from 30 to 75 V over this range to aid detection of ions
aving high mass-to-charge ratios.
For tandem mass spectrometry experiments, peptides isolated
y semi-preparative HPLC column (2.1 mm id, 15 cm length, 3.5 m
ead size, 150 A˚ pore size, Hichrom, UK) were lyophilised and
econstituted in 1:1 methanol:water with 0.1% (v/v) formic acid.
 l aliquots were loaded into the end of a platinum coated, pulled,
orosilicate capillary to which a voltage of approximately 1 kV
as applied, resulting in spraying ﬂow rates of around 20 nl/min.
he hexapole collision cell of the Quattro II mass spectrometer
ontained argon gas at a pressure of 4 × 10−3 mbar and collision
nergies were varied between 20 and 30 V to give optimum daugh-
er ion abundance. MS2  was scanned between m/z  50 and 2500
20 s scan time) and at least 50 scans were summed to give the
nal spectra.
.3. Edman degradation
Fractions containing peptides of interest were identiﬁed by ESI-
S  by use of platinum-coated borosilicate glass capillaries (see
bove). Edman degradation was performed by means of an Applied
iosystems automated protein sequencer. PTH amino acids were
eparated using the manufacturer’s PTH C18 column and a 140 C
PLC system.
.4. Molecular dynamics simulations
The NMR  structure of the murine prion protein, residues
24–226, was downloaded from the protein data bank (PDB
D 1AG2) [24]. This structure was used as a starting point for
imulations by use of the AMBER suite of molecular dynamics
oftware (version 7) [33]. We  used the Amber99 all atom force
eld supplemented with Glycam04 parameters for carbohydrates
34]. A pdb ﬁle for the Gal-Glu carbohydrate was constructed by
se of the on-line glycoprotein builder at the Glycam web  site
http://glycam.ccrc.uga.edu/ccrc/) and a merged pdb ﬁle was  cre-
ted using Swiss PDB Viewer (DeepView) [35]. During creation of
olecular topology the carbohydrate was attached to the -carbon
f Lys193 of the murine PrP by use of the AMBER software, as either
R or 5S stereoisomer. This resulted in artiﬁcially large bond lengths
etween the protein and the carbohydrate which were removed
uring energy minimisation and equilibration. Wildtype murines Spectrometry 345– 347 (2013) 132– 141
PrP was also subjected to molecular dynamics simulations starting
from the 1AG2 pdb coordinate ﬁle with no adjustments.
Starting structures were extensively energy minimised to
remove energy hot spots and, in the case of the modiﬁed structure,
to reduce the bond length between the carbohydrate and the pro-
tein; bonds to hydrogen atoms were ﬁxed during this procedure.
Structures were then equilibrated in silico to 37 ◦C and molecular
dynamics was  carried out at 37 ◦C for 10 ns for each structure. A
Born approximation of implicit solvent was used to expedite sim-
ulations [36] whilst a simulation of 200 mM salt was  included to
maintain buffering. Coordinates were output every 10 ps during
each simulation and every structure was  analysed for root-mean-
squared (RMS) deviation from starting and mean structures, for
hydrogen bonds and for change in phi–psi angles. Molecular trajec-
tories were analysed using AMBER software or with VMD  analysis
software [37] and ﬁgures were built using VMD  or MOLMOL  [38].
3. Results
3.1. Mammalian-expressed PrP contains a post-translational
modiﬁcation in the C-terminal region
In our laboratory, a long-term strategy for the production of
prion protein for structural analysis has been the over-expression of
murine recPrP by stably transfected CHO cell lines. The recPrP pro-
duced has been mutated, at the DNA level, to remove the sites of
N-linked glycosylation (Asn180Thr and Asn196Thr) and to prevent
addition of the glycosylphosphatidylinositol membrane anchor by
removing the C-terminal signal sequence. The N-terminal signal
sequence is retained and the protein is thus secreted from the cells
and it accumulates in the culture medium, from which it can be
puriﬁed to allow both structural and functional analyses.
After expression of murine recPrP in CHO cells, several proteins
can be detected by anti-PrP antibodies by Western blotting [31].
A proportion of the full length protein molecules, mass ∼23 kDa,
are cleaved speciﬁcally by the action of an unknown protease to
result in polypeptides of mass ∼9 kDa and ∼14 kDa equating to the
N-terminal and C-terminal portions of the protein respectively. Pre-
viously published mass spectrometric analyses showed that this
cleavage corresponds exactly to that taking place constitutively
in vivo and occurs between residues 109 and 110 [31]. During these
studies, the N-terminal, 9 kDa fragment co-puriﬁed with full length
recPrP by Ni-IMAC and cation exchange chromatography, owing
to similar charge and metal ion binding properties. Our previous
analysis of the N-terminal fragment demonstrated the presence
of a novel post-translational modiﬁcation [19]: proline 44 can be
speciﬁcally modiﬁed to 4-hydroxyproline in an enzymatic reaction
requiring both a consensus sequence and polyproline II structure
in the substrate (see Fig. 1a). The C-terminal, 14 kDa fragment
was  lost during our puriﬁcation protocol, however, limited trypsin
digestion of full length recPrP produced an analogous polypeptide
spanning residues 110–228, i.e.,  from the in vivo cleavage site to
within 2 residues of the C-terminus of the mature length protein.
This allows the characterisation of the C-terminal domain of CHO
cell-expressed recPrP by online HPLC–MS.
Fig. 2(a) shows the mass spectrum of mature length CHO cell
recPrP and Fig. 2(b) shows the mass spectrum of the C-terminal
fragment of approximately 13.5 kDa generated by partial tryptic
digestion. In addition to species having the expected mass, both
spectra indicate the presence of various forms of the proteins with
masses higher than those predicted from the amino acid sequences.
In the mature length molecule, some of this heterogeneity may
be rationalised by the formation of 4-hydroxyproline at codon 44
in a proportion of the molecules (∼70%) [19]. The mass spectrum
of the 13.5 kDa, C-terminal fragment, spanning residues 110–228,
M.A. Ritchie et al. / International Journal of Mass Spectrometry 345– 347 (2013) 132– 141 135
Fig. 2. (a) Mass spectrum and, inset, deconvoluted mass spectrum of mature length, CHO cell-expressed recPrP. The theoretical mass of the unmodiﬁed protein is 22904.2 Da.
(b)  Mass spectrum and, inset, deconvoluted mass spectrum of the polypeptide spanning residues 110–228 generated by partial trypsin digestion of recPrP. The theoretical
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pectrum of mass 13,708 Da corresponds to a sodium adduct of the hydroxylated p
rom  recPrP spanning residues 185–203. The theoretical mass of this peptide is 212
owever, also reveals the presence of other post-translational mod-
ﬁcations. In addition to signals corresponding to a protein of the
orrect molecular weight for this fragment, a species is present that
s 16 Da higher in mass suggesting oxidation of another amino acid.
 third species is also evident that is 340 Da higher in mass than that
redicted. The absence of a fourth species a further 16 Da higher
uggests that this third species may  arise through the addition of
24 Da to the protein having the oxidised amino acid, or that addi-
ion of a species of 340 Da may  occur instead of oxidation at the
ame site. We  noted these modiﬁcations in our previous mass spec-
rometric investigations, without being able fully to characterise
hem [31]. Other higher molecular weight species that are evident
n the deconvoluted mass spectra of Fig. 2(a) and (b) correspond
o sodium or potassium adducts.
In order to locate the site(s) of the novel C-terminal modiﬁca-
ions, mature length recPrP was reduced and alkylated, dialysed
o remove excess reagents and was extensively digested with
rypsin. A sample of the resulting peptides was  analysed by cap-
llary HPLC–MS. We  observed various peptides having massest mass, proteins heavier by 16 and 340 Da are evident. The peak in the deconvoluted
. (c) Mass spectrum and, inset, deconvoluted mass spectrum of the tryptic peptide
a. Close eluting peptides a further 16 and 340 Da higher in mass can also be seen.
corresponding to those predicted from the theoretical structure,
in addition to 2 peptides that had co-eluting species 16 Da higher
in mass of signiﬁcant abundance. One of these corresponded to
the peptide containing the previously identiﬁed 4-hydroxyproline
residue (data not shown). The other had a mass of 2124.18 Da, in
close agreement to the predicted tryptic peptide spanning residues
185–203, of mass 2124.29 Da, which is generated through a missed
tryptic cleavage at Lys193. Fig. 2(c) shows the summed mass spec-
trum containing signals corresponding to the unmodiﬁed peptide,
its oxidised equivalent at 16 Da higher in mass, as well as a third
peptide eluting from the HPLC column 1 min earlier, a further
324 Da higher in mass. Thus, the modiﬁed amino acid occurs within
the sequence of 185–203 of recPrP.
3.2. Lys193 is speciﬁcally hydroxylated with subsequent
disaccharide addition
The recPrP tryptic digest was  separated on a semi-preparative
reversed phase column and fractions were collected. Fractions
136 M.A. Ritchie et al. / International Journal of Mass Spectrometry 345– 347 (2013) 132– 141
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type fragment ions allowing partial sequence information to be
derived and conﬁrming the identity of the peptide. The CAD spec-
trum of the hydroxylated equivalent is similar, but crucially peaks
Fig. 4. CAD mass spectra of peptides of sequence QHTVTTTTJGETFTETDVK. (a)ig. 3. Edman sequencing chromatograms of cycle 9 from the recPrP tryptic peptide
nd  340 Da (lower trace) higher in mass. In the upper trace a major peak correspon
orresponding to PTH–-hydroxylysine can be seen. In the lower trace, an unknow
ontaining the three peptides of interest – Gln185-Lys203 and the
wo modiﬁed equivalents – were identiﬁed by ofﬂine nanospray
ass spectrometry. The peptides were analysed by N-terminal
dman sequencing, which demonstrated that each had the same
-terminal peptide sequence and conﬁrmed the identities of the
eptides. At cycle 9, corresponding to Lys193, however, there were
igniﬁcant differences in the Edman cycles. The chromatograms for
his cycle in each of the peptides are shown in Fig. 3. The upper trace
hows cycle 9 from the unmodiﬁed peptide where a major peak
orresponding to phenylthiohydantoin (PTH)–lysine can be seen.
lthough there are signiﬁcant background peaks from other amino
cids, subtraction of data from the previous cycle clearly indicates
he presence of lysine in this cycle (data not shown). In the middle
race in Fig. 3, the peak for PTH–lysine is signiﬁcantly reduced in
ize whilst a different peak, eluting at 15.5 min, just prior to DPTU, is
resent. This chromatogram is from the sequencing experiment on
he oxidised peptide (M + 16 Da) and, by comparison to literature
alues provided by the PTH column manufacture, the new peak is
een to correspond to the PTH derivative of -hydroxylysine. This
eak is almost coincident with an unknown peak, present in all
ycles, presumably the result of side reactions during the labelling
tep. The lower trace in Fig. 3 shows the Edman chromatogram from
ycle 9 of the species 340 Da heavier in mass than the unmodi-
ed peptide. A different peak of low intensity, eluting at around
1 min  just after PTH–tyrosine, is present in this chromatogram
ut does not correspond to any known PTH derivative of modiﬁed
ysine by comparison with literature values [39]. In collagen and
roteins possessing collagenous domains, a common modiﬁcation
o -hydroxylysine residues is addition of the disaccharide Gal-Glu
40], which would cause the required mass shift of 324 Da. How-
ver, the elution position of PTH–-hydroxylysine with covalent
ddition of the disaccharide Gal-Glu, is not known since it is often
ot seen during Edman degradation [41,42].
To provide further proof for the 2 different modiﬁcations being
resent on Lys193, the 3 isolated peptides were subjected to col-
isionally activated dissociation (CAD) experiments by means of
andem mass spectrometry (MS/MS). The three CAD spectra, cor-
esponding to peptides that were unmodiﬁed, 16 Da and 340 Da
igher in mass than predicted, are shown in Fig. 4(a)–(c) respec-
ively. In each case the triply charged ion was used as the precursor
on and is indicated on the spectra with an asterisk. The CAD
pectrum of the unmodiﬁed peptide has multiple neutral losses
f water from the precursor ion, presumably from the threonineing residues 185–203 (upper trace) and the peptides a further 16 Da (middle trace)
o PTH–lysine is evident. In the middle trace a peak eluting at around 15.5 min, and
 is evident eluting just after PTH–tyrosine.
sidechains. Also evident are both singly and doubly charged y-J  = lysine, precursor ion is 708.0 (b) J = hydroxylysine, precursor ion is 713.4 (c) J = O-
glycosylated hydroxylysine, precursor ion is 821.4. The precursor ion is labelled with
an asterisk on each spectrum. Y-type fragment ions are seen in all spectra, in addi-
tion to loss of water. In (c) loss of 2 consecutive hexose residues can be seen in both
doubly and triply charge states.
f Mass Spectrometry 345– 347 (2013) 132– 141 137
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Fig. 5. (a) Overlay of cycle 9 from the putative glycosylated recPrP tryptic peptide
(upper trace) and cycle 9 from the known O-linked glycosylated peptide from tryp-
tic digestion of complement component C1q. Despite contamination from various
amino acids, including tyrosine, a peak corresponding to the ‘unknown’ peak in
the recPrP peptide cycle is evident. (b) CAD spectrum of the tryptic peptide from
human complement component C1q of sequence G95IBGIJGTJGSPGNIK110 whereM.A. Ritchie et al. / International Journal o
orresponding to y2+18 − y2+14 have shifted upwards in mass by 16 Da.
2+
17 and y
2+
15 now appear in the same place as y
+
8 and y
+
7 respectively,
ccounting for the relative increase in the size of these signals. A
eak at m/z  1270 is assigned as y+11 and corresponds to fragmenta-
ion at the N-terminal side of the hydroxylysine residue. This peak,
n conjunction with the peak at 1126.5, assigned as y+10, proves that
he hydroxylation is at Lys193.
The CAD spectrum of the peptide with an additional 340 Da
hows only limited sequence-speciﬁc fragmentation. Instead, the
pectrum is dominated by the loss of both water and 2 sequential
osses of mass 162 Da. This is the mass of a hexose unit, and these
ignals, occurring as both neutral losses (3+ charge state) and as
ingly charged fragments, resulting in 2+ peptide fragment ions,
emonstrate the presence of a disaccharide on this peptide. The
osition of peaks assigned as y+7 − y+10 remain unchanged relative to
he CAD spectrum of the unmodiﬁed peptide and indicate that the
isaccharide is attached N-terminally to Glycine 194. The absence
f the y+11 peak at m/z 1270 suggests that Lys193 is also the site of
ttachment of the disaccharide.
.3. Comparison with complement-component C1q demonstrates
ysine glycosides are present in CHO-cell recPrP
In order to conﬁrm our Edman degradation and MS  assignments
or lysine modiﬁcations, we sought a standard protein that carries
imilar modiﬁcations. Complement component C1q exists in vivo
s a multimeric protein complex held together by triple helices
ormed by the N-terminal collagenous regions of the protein. These
egions have previously been shown to contain a number of hydrox-
lysine residues with covalently attached dissacharides [43,44].
hus, to provide a control sample for comparison of mass spec-
rometry and Edman degradation data, C1q from human serum
as digested with trypsin and peptides containing lysine glyco-
ides were isolated. The C1q subunit A-derived peptide spanning
esidues 95–110 contains 2 known sites of hydroxylysine formation
nd measurement of the mass of this peptide by mass spectrometry
emonstrated that hydroxylation and glycosylation had occurred
t both sites. This peptide was subjected to both Edman degrada-
ion and MS/MS  experiments. Fig. 5(a) shows the chromatogram
f cycle 9, the second glycosylated hydroxylysine residue, of the
dman degradation and shows clearly a peak eluting at around
1 min, just after PTH tyrosine. No other peak is seen that can-
ot be accounted for by contamination of the chromatogram by
ackground levels of amino acids. This peak has the same reten-
ion time as that of the ‘unknown residue’ in the PrP-derived
eptide (Fig. 3(c)) and strongly suggests that this peak is caused
y the PTH derivative of hydroxylysine modiﬁed with the disac-
haride galactose-glucose. The relatively weak signals in both the
1q peptide and the PrP peptide is probably caused by chem-
cal degradation of the amino acid under the acidic conditions
f the cleavage reactions and, as mentioned previously, glyco-
ylated hydroxylysine is known to be poorly covered by Edman
egradation. We  also analysed the C1q-derived peptide by mass
pectrometric methods and Fig. 5(b) shows the CAD spectrum of
he C1q peptide. As with the PrP peptide (Fig. 4(c)), losses cor-
esponding to hexose residues can clearly be seen. In this case,
onsecutive losses of 4 hexose units are seen, rationalised by the
resence of 2 glycosylated hydroxylysine residues. In any case,
oth Edman degradation and mass spectrometric analysis of this
1q peptide is analogous to the analyses of the PrP-derived pep-
ide providing conclusive evidence that Lys193 of recPrP carries
oth -hydroxylation in a proportion of molecules and subsequent
ddition of a disaccharide, probably galactose–glucose, in a further
roportion.B  = 4-hydroxyproline and J = O-glycosylated -hydroxylysine. Loss of up to 4 con-
secutive hexose residues can be seen, in both doubly and triply charged states
demonstrating the presence of 2 sites having hydroxylysine linked to disaccharides.
3.4. Molecular modelling of PrP-Hyl-Gal-Glu
In order to probe the effect that glycosylation of Lys193 may
have on the structure of PrP, we  performed molecular dynamics
simulations by use of the AMBER suite of programmes. Starting
from the coordinates of murine PrP (PDB code 1AG2), we  attached
the disaccharide Gal-Glu in the delta position of Lys193 by use of
the online tool available in the Glycam suite (http://glycam.ccrc.
uga.edu/AMBER/index.html) and the molecular preparation (LEaP)
module of AMBER. In principle, delta-hydroxylation of lysine could
result in one of two stereoisomers, designated 5R and 5S. In
collagen, -hydroxylysine is of the 5R type, whereas the lysine
hydroxylation that is carried out by the enzyme JMJD6 results in the
5S stereoisomer [45]; thus the hydroxylysine could theoretically be
of either type, although the 5R isomer (as found in collagen) is most
likely. Nevertheless, we  made models of both types of modiﬁed PrP
and the resulting coordinates were extensively minimised to opti-
mise the lysine-disaccharide linking bonds and to remove any steric
clashes introduced during the modiﬁcation process. The structure
of the gal-glu--hydroxylysine residue is shown in Fig. 6(a) whilst
Fig. 6(b) and 6(c) show ribbon structures of the post translation-
ally modiﬁed and energy minimised protein structures used as
the starting point for simulations of the 5R and 5S stereoisomers
respectively.
Molecular dynamics were performed over 10 ns for each
stereoisomer of modiﬁed PrP and a similar simulation was per-
formed on unmodiﬁed, wildtype, murine PrP. For all 3 proteins, we
calculated the RMS  deviation of the backbone atoms compared to
the starting structure and also compared to a structure that was
averaged over the course of each simulation. The results of these
analyses are shown in Fig. 7. In line with previously published
138 M.A. Ritchie et al. / International Journal of Mass Spectrometry 345– 347 (2013) 132– 141
F Gal-Gl
w  stereo
w e units
r
ﬂ
s
t
i
p
r
r
l
a
c
s
i
s
t
i
i
s
m
r
u
s
s
oig. 6. (a) Schematic diagram of a -hydroxylysine residue with the disaccharide 
ith  lys193 and the disaccharide Gal-Glu shown in ball and stick form for 5R and 5S
as  used. Lys193 was modiﬁed to attach a -oxygen atom followed by the 2 hexos
esults [46,47], wildtype murine PrP shows relatively minor RMS
uctuations from the average structure and these dynamic excur-
ions are most pronounced in the loop regions of the protein linking
he regions of globular secondary structure. The loop region link-
ng the second beta strand (2) to the second alpha helix (2) is
articularly mobile relative to other regions of the protein.
Compared with wildtype murine PrP, simulations of PrP car-
ying the disaccharide at lys193 shows similar mobility in the
egion of the protein around the modiﬁed amino acid. The 2–3
oop appears more ﬂexible when the disaccharide is attached as
 5S stereoisomer whilst the 5R stereoisomer, usually found in
ollagen, results in slight stabilisation of this loop region. In the
imulations of the 5S stereoisomer, the ﬁrst -helix (1) also shows
ncreased dynamic excursions although the helical structure is pre-
erved. In the 3-dimensional structure, this helix is located next to
he 2–3 loop region and the site of the modiﬁcation, indicat-
ng that the ﬂexibility of this loop region in this model also causes
ncreased mobility in helix 1. Conversely, the 2–2 loop region
hows substantially reduced mobility in the simulations of both
odiﬁed proteins, as evidenced by small RMS  deviations around
esidues 163–173 relative to the averaged structure for each sim-
lation (Fig. 6(b)). The 2–2 loop is stabilised regardless of the
tereoisomeric nature of the hydroxylysine, suggesting a long range
tabilisation of this region of the protein as a result of the presence
f O-glycosylation on Lys193. Recent studies have also shown longu covalently attached to the -oxygen. (b) and (c) Ribbon diagrams of human PrP
isomers respectively. The NMR  structure of murine prion protein (PDB code 1AG2)
 and the structure was  energy minimised using the AMBER force ﬁeld.
range stabilisation of this loop by changes to amino acids in other
regions of PrP [48,49].
The differences in mobility of the 2–2 loop regions of the three
proteins can be seen clearly in Fig. 8, where these regions of the
average structure of each protein are shown in detail alongside the
loop region of the starting structure. For the average structures from
the 3 simulations, the diameter of the backbone trace indicates the
RMS  deviation calculated relative to the average structure over the
course of each simulation. In the simulations of all three proteins a
short 3–10 helix is formed between residues 165 and 168 and this
structure is substantially more stable when hydroxylysine glycosy-
lation is present at Lys193. The stability of the 2–2 loop region of
the prion protein is believed to be critical for the structural conver-
sion to PrPSc. Indeed, transgenic mice expressing protein in which
the mobility of this loop has been constrained developed sponta-
neous prion disease [50,51], strongly suggesting that a rigid 2–2
loop is a factor governing susceptibility to disease.
4. Discussion
Hydroxylysine and its O-glycosylated derivative commonly
occur in collagen but have been found in a variety of other pro-
teins that possess collagenous domains, such as mannose binding
protein (MBP), pulmonary surfactant protein D (SP-D) and comple-
ment component C1q. Hydroxylation takes place within consensus
M.A. Ritchie et al. / International Journal of Mass
Fig. 7. Graphs showing per residue RMS  deviations of backbone atoms from (a)
t
t
m
s
a
p
t
F
c
s
m
s
t
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odiﬁed protein () and the 5S stereoisomer disaccharide-modiﬁed protein (©).equences of Xxx-Lys-Gly by the enzyme lysyl hydroxylase [40],
lthough this motif appears in many proteins without action, so
resumably some other indicator, such as the correct conforma-
ion, is required for hydroxylation. This is certainly the case with
ig. 8. Close up of the 2–2 loop region of PrP from (a) the NMR structure of murine P
ode  1AG2 (b) the averaged structure from molecular dynamics simulation of wildtype m
imulations of murine PrP modiﬁed to incorporate hydroxylation of lysine 193 with the d
olecular dynamics simulations of murine PrP modiﬁed to incorporate hydroxylation o
tructures shown in panels (b)–(d) the loop region has been correctly oriented by ﬁtted t
he  per-residue RMS  deviations from the averaged structures calculated over the course 
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the previously identiﬁed hydroxylation of proline 44 of recPrP,
where action of the enzyme prolyl 4-hydroxylase demonstrated
the presence of poly-l-proline II structure in the N-terminal region
of the protein [19,20]. In PrP, the only site that fulﬁls the consensus
sequence for lysyl hydroxylation is Thr192-Lys193-Gly194.
In pro-collagen, addition of monosaccharides, speciﬁcally galac-
tose followed by glucose (Fig. 6(a)), to -hydroxylysine by
carbohydrate transferases results in collagenous hydroxylysine
residues having no, one or two  hexose units attached. Hydrox-
ylysines in proteins other than collagen tend to have only the entire
disaccharide attached implying a separate transferase may  act on
these proteins. Within collagen the exact role of hydroxylysine is
not clear, but these residues have been shown to promote ﬁbril
strength through the formation of inter-chain, covalent bonds [52].
The role of the carbohydrates appears to be to prevent these inter-
chain links. In other proteins the role of hydroxylysine residues may
also be to mediate multimerisation of protein chains.
Detection of carbohydrate attachment to hydroxylysine has pre-
viously been based on a range of techniques such as resistance
to trypsin digestion, absent residues during Edman sequencing
or peptide mass measurement by mass spectrometry. Peptide
mass ﬁngerprinting of a trypsin digest of SP-D showed a vari-
ety of adducts of mass 340 Da on certain peptides, suggesting
hydroxylation and disaccharide addition in positions that this mod-
iﬁcation was expected to occur [53]. To our knowledge, our work
represents the ﬁrst identiﬁcation of the elution time of PTH–Glu-
Gal-hydroxylysine during Edman sequencing but other studies
have also made use of MS/MS  techniques to identify disaccharide
attachment to hydroxylysine residues [41].
The subcellular site of action of lysyl hydroxylation has been
studied extensively and it is generally accepted that both prolyl
and lysyl hydroxylases work co-translationally in the ER with the
growing or nascent polypeptide chain [54] whilst glycosylation of
Hyl residues may  occur in either the ER or the golgi. Walmsley
et al., found that recPrP lacking the GPI anchor and C-terminal signal
sequence, expressed in mammalian cell lines, experienced delayed
transit to the cell surface, consistent with increased processing time
rP determined by Riek et al. [24] used as a starting point for our simulations, PDB
urine PrP residues 124–226 (c) the averaged structure from molecular dynamics
isaccharide gal-glu attached as a 5R stereoisomer (d) the averaged structure from
f lysine 193 with the disaccharide Gal-Glu attached as a 5S stereoisomer. For the
o the starting structure and the diameter of the backbone spline is proportional to
of each simulation. Amino acid side chains are shown as ball and stick models and
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n the ER or golgi [55]. The delay in protein transit is likely to account
or the extent of the modiﬁcations in our recombinant PrP, which is
imilarly mutated to remove the C-terminal signal sequence. How-
ver, the ﬁnding that a proportion of the molecules of PrPSc puriﬁed
rom the brains of scrapie infected mice were hydroxylated at Pro44
ndicated that this modiﬁcation can occur in vivo in the absence of
on-physiological mutations. It seems likely that a similarly small
ercentage of molecules will also contain hydroxylysine but estab-
ishing this is problematic due to the close proximity of Lys193
o the N-linked glycosylation site, Asn196. However, transgenic
ice have recently been created that express PrP from a gene in
hich the C-terminal signal sequence has been ablated (PrP GPI−)
nd we expect this protein to be trafﬁcked similarly to that in our
HO cell line. In mice, PrP GPI− is secreted from cells and infection
f these animals with mouse-passaged scrapie produces unusual
esults [56,57]. PrP GPI− is certainly trafﬁcked abnormally, as evi-
enced by substantially reduced N-linked glycosylation, and it is
ossible that this allows aberrant modiﬁcations, such as proline or
ysine hydroxylation, to take place in the secretory pathway. As yet,
e do not know whether PrPC (or PrPSc) produced in vivo can be
ydroxylated and glycosylated at Lys193.
An important question is how glycosylation at Lys193 might
ffect the structure of PrPC. Previous molecular dynamics simu-
ations of PrP with N-linked glycans attached suggests that the
arbohydrates are relatively ﬂexible and can perform large dynamic
xcursions without greatly inﬂuencing the tertiary structure of the
rotein [46,58]. In the current work, we ﬁnd that the glycosyla-
ion attached to Lys193 is also ﬂexible but that its presence does
ot greatly inﬂuence the motion in the protein backbone of the
oop immediately adjacent to Lys193. In one of the two stereoiso-
eric models, slightly enhanced motion in this region led to some
nstability in helix,1 but the motion was not sufﬁcient to cause
nravelling of helices 2 and 3. Conversely, there appeared to be
ong range stabilisation effects on the 2–2 loop of PrP in both 5R
nd 5S stereoisomer models, presumably as a direct result of the
resence of O-glycosylation at Lys193. A rigid 2–2 loop has been
uggested to be important for PrP conversion and we have previ-
usly found an inverse correlation between the lability of this loop
nd the ability of PrP to convert in vitro [59]. This raises the pos-
ibility that hydroxylation and subsequent glycosylation of Lys193
ay  predispose PrP to disease-speciﬁc conversion. Thus, conditions
hat one may  expect to increase these modiﬁcations, such as lack
f the C-terminal signal sequence or ER stress, may  also result in an
nhanced ability of PrP to convert. We  are currently following up
hese ideas in our laboratories.
Finally, it is interesting to note that Lys193 is only 3 residues
-terminal to the second N-linked glycosylation site within PrP,
sn196. The presence of a disaccharide attached to Lys193 may
inder carbohydrate transferases or subsequent glycan trimming
eactions at Asn196 leading to abnormal glycosylation in a percent-
ge of PrP molecules. Conversely, the presence of an N-linked glycan
t Asn196, may  prevent disaccharide addition to any hydroxylysine
esidue formed at codon 193. Which event is likely to predominate,
f either, will depend greatly on the order of modiﬁcation events in
he ER/golgi complex.
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